Negotiations between the U.K. government and the pharmaceutical industry have broken down with no agreement over the level of rebates companies must pay back to the government under the current voluntary pricing scheme. The two sides have been locked in discussions since April, when the government agreed to bring forward a midterm review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).